Eltrombopag Powder for Suspension and Interferon Alfa-2b Powder for Injection

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

For patients with chronic hepatitis C, using eltrombopag together with interferon alfa-2b may worsen liver function and increase liver problems. The risk is greatest in patients who already have advanced liver disease or cirrhosis. Liver failure may occur, resulting in complications like ascites (accumulation of fluid in the abdominal cavity), hepatic encephalopathy (confusion, altered consciousness, or coma due to accumulation of toxic substances in the bloodstream), variceal hemorrhage (bleeding in the esophagus or stomach due to dilated veins), and bacterial peritonitis (infection of the inner abdominal wall lining). Talk to your doctor if you have any questions or concerns. Your doctor may already be aware of the risks, but has determined that this is the best course of treatment for you and is monitoring you closely for any potential complications. You should seek immediate medical attention if you have fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, abdominal pain, dark colored urine, light colored stools, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

MONITOR CLOSELY: In chronic hepatitis C patients with advanced liver disease, coadministration of eltrombopag with interferon-based therapy may increase the risk of adverse reactions including potentially fatal hepatic decompensation and thromboembolic events. In two controlled clinical trials of thrombocytopenic patients with chronic hepatitis C, adverse events related to hepatic decompensation such as ascites, hepatic encephalopathy, variceal hemorrhage, and spontaneous bacterial peritonitis occurred more frequently in the group receiving antiviral treatment with eltrombopag than the group receiving placebo concomitantly (11% vs. 6%). Patients with albumin levels =10 at baseline had a three-fold greater risk of hepatic decompensation and increased risk of a fatal adverse event compared to those with less advanced liver disease. Furthermore, the proportion of these patients who achieved a sustained virologic response compared with placebo were modest relative to the group overall.

MANAGEMENT: In chronic hepatitis C patients with poor liver function (albumin levels =10) at baseline, eltrombopag should only be administered with interferon-based therapy after careful consideration of the potential benefits versus associated risks, and patients should be monitored closely for signs and symptoms of hepatic decompensation. Eltrombopag should be discontinued if antiviral therapy is withdrawn for hepatic decompensation.

Eltrombopag Powder for Suspension

Generic Name: eltrombopag

Brand name: Promacta

Synonyms: Eltrombopag

What is Eltrombopag Powder for Suspension?

Interferon Alfa-2b Powder for Injection

Generic Name: interferon alfa-2b

Brand name: Intron A

Synonyms: Interferon alfa-2b, Interferon Alfa-2b

What is Interferon Alfa-2b Powder for Injection?